Pharmacokinetics of pyridostigmine in a child with postural tachycardia syndrome

Pediatrics

Volumn 118, Issue 5, 2006, Pages

  Filler, Guido ^a,c   Gow, Robert M ^a   Nadarajaha, Renisha ^a   Jacob, Pierre ^a   Johnson, Gillian ^b   Zhang, Yan Ling ^b   Christians, Uwe ^b  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Acetylcholine; Autonomic; Children; Nervous system; Pharmacokinetics; Tachycardia

Indexed keywords

CARVEDILOL; CLONIDINE; FLUDROCORTISONE; FOSINOPRIL; MACROGOL; MIDODRINE; PHYSOSTIGMINE; CHOLINESTERASE INHIBITOR; PYRIDOSTIGMINE;

ADOLESCENT; ANAMNESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONSTIPATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MALE; MYASTHENIA; NAUSEA; ORTHOSTATIC HYPOTENSION; POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE; TACHYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BODY POSTURE; CASE REPORT; METABOLISM; PRESCHOOL CHILD; SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; MALE; POSTURE; PYRIDOSTIGMINE BROMIDE; SYNDROME; TACHYCARDIA;

EID: 33750957327     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-0904     Document Type: Article

References (13)

1. Makai A, Tahin T, Simor T, Csanadi Z, Rudas L. Postural tachycardia syndrome [in Hungarian] Orv Hetil. 2005;146:515-520
2. Jordan J. Effect of water drinking on sympathetic nervous activity and blood pressure. Curr Hypertens Rep. 2005;7:17-20
3. Freitas J, Santos R, Azevedo E, Costa O, Carvalho M, de Freitas AF. Clinical improvement in patients with orthostatic intolerance after treatment with bisoprolol and fludrocortisone. Clin Auton Res. 2000;10:293-299
4. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group [published correction appears in JAMA. 1997;278:388]. JAMA. 1997;277:1046-1051
5. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120-124
6. Shannon JR, Jordan J, Diedrich A, et al. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101:2710-2715
7. Raj SR, Black BK, Biaggioni I, Harris PA, Robertson D. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation. 2005;111:2734-2740
8. Singer W, Opfer-Gehrking TL, McPhee BR, Hilz MJ, Bharucha AE, Low PA. Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2003;74:1294-1298
9. Aquilonius SM, Hartwig P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet. 1986;11:236-249
10. Mathews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235
11. Grubb BP, Kanjwal Y, Kosinski DJ. The postural tachycardia syndrome: a concise guide to diagnosis and management. J Cardiovasc Electrophysiol. 2006;17:108-112
12. Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513-518
13. Zhang YL, Bendrick-Peart J, Strom T, Haschke M, Christians U. Development and validation of a high-throughput assay for quantification of the proliferation inhibitor ABT-578 using LC/LC-MS/MS in blood and tissue samples. Ther Drug Monit. 2005;27:770-778